Stay updated on Safety Efficacy Pegvaliase Self-Injection PKU Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Pegvaliase Self-Injection PKU Clinical Trial page.

Latest updates to the Safety Efficacy Pegvaliase Self-Injection PKU Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page presents the completed Phase 3 pegvaliase extension study for adults with phenylketonuria, including its design, outcomes, eligibility criteria, and study locations. It also provides results-related information and study documents.SummaryDifference51%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0; the study record remains inaccessible with a 403 Forbidden message.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide notice announces NIH’s transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now displays a 403 Forbidden error with a minimal header, replacing the usual study details and indicating restricted access.SummaryDifference17%

Stay in the know with updates to Safety Efficacy Pegvaliase Self-Injection PKU Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Pegvaliase Self-Injection PKU Clinical Trial page.